Key facts
- Alyssum Therapeutics’s last known valuation is $13.3M (Mar 2017).
- It has raised $32.7M; the latest was Later Stage VC ($28.0M) in Jan 2025.
- Notable investors include Accel, REMUS Capital, FemHealth Ventures, Romulus Capital, Aarin Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Alyssum Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Alyssum Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alyssum Therapeutics
Developer of supramolecular therapeutics designed for cancer patients. The company offers treatments and antibody drugs to treat lung, testicular, colorectal, and childhood cancers, its therapeutics use supra-molecular technology to design anti-cancer drugs that home in on the tumor and modulate the tumor immune response, enabling oncologists to outsmart cancer cells in patients by activating the immune system.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2011
- Employees
- 4
- Website
- alyssumtx.com/
- Ownership
- Privately Held (backing)
Alyssum Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alyssum Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alyssum Therapeutics in its N-PORT filings yet. We sweep new filings monthly.